abstract |
Disclosed is a modified kringle 5 peptide having a long-term effect for the treatment of diseases related to angiogenesis. According to the present invention, a modified anti-angiogenic peptide is provided, which peptide reacts with an amino group, hydroxyl group, or thiol group of a blood component to form a stable covalent bond. Have In another embodiment, the peptide is a kringle 5 peptide. Another embodiment of the present invention is a method for extending the in vivo half-life of an anti-angiogenic peptide comprising: attaching a reactive group to the peptide, and the reactive group Reacting with functional groups of blood components to form a covalent bond, thereby forming a stable in vivo conjugate having an in vivo half-life that is longer than the in vivo half-life of this anti-angiogenic peptide alone. Include. [Selection figure] None |